NXY-059
| CAS No. | 168021-79-2 | Cat. No. | BCP02401 |
| Name | NXY-059 | ||
| Synonyms | NXY 059;NXY059;Cerovive;Disufenton sodium; | ||
| Formula | C11H13NNa2O7S2 | M. Wt | 381.33 |
| Description | NXY-059 is more soluble than the spin trapping agent α-phenyl-N-tert-butyl nitrone (PBN). [1] In an in vitro blood-brain barrier (BBB) model, 250 mM of NXY-059 administered at the onset or up to 4 h after oxygen glucose deprivation (OGD) produces a significant reduction in the increased BBB permeability caused by OGD. Furthermore, OGD produces a huge influx of tissue plasminogen activator across the BBB, which is substantially reduced by NXY-059. | ||
| Pathways | Others Pathway | ||
| Targets | Others | ||
Structure
Part data of this page collected from the open network resources, so Biochempartner can not guarantee its accuracy.
For product details of different batches, please contact our Customer
- Service & Tech Support:orders@biochempartner.com
- Website:www.biochempartner.com
Products are for research use only and not for human use. We do not sell to patients.